Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) announced a one-year extension of promotional services terms with Sandoz Canada Inc. for its Vistitan eye drops, which treat elevated eye pressure in glaucoma patients. This extension builds on a four-year relationship, reflecting a consistent growth of over 30% CAGR for the Vistitan brand during this period. Aequus aims to expand its portfolio in the Canadian eye care market by investing in new strategic products and partners.
- 1-year extension of promotional services with Sandoz Canada.
- Vistitan brand has grown over 30% CAGR in the last four years.
- Focus on expanding product offerings in the Canadian eye care market.
- None.
VANCOUVER, British Columbia, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce a 1-year extension of terms with Sandoz Canada Inc., with option for parties to renew, for promotional services related to PrVistitanTM (bimatoprost
“The contract extension recognizes a 4-year relationship that has seen Aequus’ commercial team consistently grow the Vistitan brand by >
Grant Larsen, Chief Commercial Officer added, “This extension aligns with our mission to identify complementary and innovative products that provide value to patients and eye care professionals in Canada. We continue to invest in our team and capacity to scale up with additional strategic products and partners in the growing Canadian eye care market.”
ABOUT AEQUUS PHARMACEUTICALS INC.
Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas. For further information, please visit www.aequuspharma.ca.
VistitanTM: Trademark owned or used under license by Sandoz Canada Inc.
FORWARD-LOOKING STATEMENT DISCLAIMER
This release may contain forward-looking statements or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including, without limitation, statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “potential” and similar expressions. Forward- looking statements are necessarily based on estimates and assumptions made by us in light of our experience and perception of historical trends, current conditions and expected future developments, as well as the factors we believe are appropriate. Forward-looking statements include but are not limited to statements relating to: the implementation of our business model and strategic plans; revenue growth trends into the future; expected timing for product launches; the Company’s expected revenues; the regulatory approval of its products; the Company’s ability to attract international partners; and ongoing discussions with and the Company’s ability to secure potential partners to further grow our product portfolio. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by Aequus, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements. In making the forward looking statements included in this release, the Company has made various material assumptions, including, but not limited to: obtaining regulatory approvals; general business and economic conditions; the Company’s ability to successfully out license or sell its current products and in-license and develop new products; the assumption that the Company’s current good relationships with third parties will be maintained; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; market competition; the products and technology offered by the Company’s competitors; the impact of the coronavirus (COVID-19) on the Company’s operations; and the Company’s ability to protect patents and proprietary rights. In evaluating forward looking statements, current and prospective shareholders should specifically consider various factors set out herein and under the heading “Risk Factors” in the Company’s Annual Information Form dated April 30, 2021, a copy of which is available on Aequus’ profile on the SEDAR website at www.sedar.com, and as otherwise disclosed from time to time on Aequus’ SEDAR profile. Should one or more of these risks or uncertainties, or a risk that is not currently known to us materialize, or should assumptions underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by applicable securities laws. Investors are cautioned that forward-looking statements are not guarantees of future performance and are inherently uncertain. Accordingly, investors are cautioned not to put undue reliance on forward looking statements.
Contact Information:
Aequus Investor Relations
Email: investors@aequuspharma.ca
Phone: 604-336-7906
FAQ
What recent news did Aequus Pharmaceuticals announce regarding Sandoz Canada?
How much has the Vistitan brand grown in the past four years?
What product does Vistitan treat?
What is Aequus Pharmaceuticals' focus in the market?
What are the stock symbols for Aequus Pharmaceuticals?
